The expenses associated with cancer care in the United States are staggering and only expected to climb.
The expenses associated with cancer care in the United States are staggering and only expected to climb. In 2010, the total cost was $125 billion. By 2020, with more individuals living with cancer as a chronic disease, costs are expected to grow by 36% and exceed $170 billion. Faced with escalating costs, the government, payors, and providers are engaging in various activities to test different reimbursement methodologies for cancer care.
But full transition to value-based payments in oncology will continue to be an evolution, not a revolution — and collaboration is key. The aim is to shift the economics from a fee-for-service environment (buy and bill) to one that reimburses for quality, efficiency, and a lower cost of care. Typically, we see payors and providers collaborating on the following types of value-based reimbursement models:
Read the full story here: http://bit.ly/QI7k2z
Source: EGG Management Consultants
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More